-
ApolloBio’s HPV Therapeutic Vaccine VGX-3100 Gets NMPA Green Light for Clinical Trial
•
ApolloBio Corp., a joint stock company of China’s leading cephalosporin manufacturer Shandong Jincheng Pharmaceutical and Chemical Co., Ltd (SHE: 300233), has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for VGX-3100. This drug, hailed as the world’s first therapeutic vaccine for human papillomavirus…
-
Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100
•
Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval for its innovative therapeutic vaccine VGX-3100. This vaccine, which targets HPV-16/18 related anal precancerous lesions, is a significant advancement in the treatment landscape for conditions associated with Human Papillomavirus (HPV). The vaccine’s approval follows a…
